Los puntos clave no están disponibles para este artículo en este momento.
Targeting Fyn can reverse memory deficits found in AD mouse models, and rescue synapse density loss characteristic of the disease. Thus, AZD0530 is a promising candidate to test as a potential therapy for AD.
Kaufman et al. (Tue,) studied this question.